iDFS Benefit with Ribociclib Plus Nonsteroidal Aromatase Inhibitor in Patients with HR-positive, HER2-negative Early Breast Cancer By Ogkologos - November 14, 2024 866 0 Facebook Twitter Google+ Pinterest WhatsApp Final invasive disease-free survival results from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Adding Gemcitabine to Cisplatin Once per Week Concurrently with IMRT Significantly... April 17, 2024 Detecting multiple cancers with a ‘simple’ blood test: Where are we? April 14, 2022 Why Have Thyroid Cancer Diagnoses Spiked for US Women? September 28, 2021 Population-based lung cancer screening can reduce mortality in people who have... March 27, 2026 Load more HOT NEWS FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy EMA Recommends Granting a Marketing Authorisation for Poherdy Mosunetuzumab Plus Polatuzumab Vedotin Shows Promise for Patients with Aggressive Relapsed... Cancer Research UK thanks Tania Bryer for a decade of fundraising...
